Critical Path Institute (C-Path) is a non-profit organization created to improve the drug development process; its consortia include more than 1,600 scientists from government regulatory and research agencies, academia, patient organizations, and bio-pharmaceutical companies.
[2][3][4][5] The U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative in 2004 to transform the way FDA-regulated medical products are developed, evaluated, and manufactured.
[5][7] In the interest of national and global public health, C-Path develops large databases of aggregated clinical trial data that can be used to study disease progression.
[5][8][9][10] C-Path programs are focused on reducing the time, cost, and risk of drug development and regulatory review.
The Board of Directors includes Robert M. Califf, Wainwright Fishburn, Timothy R Franson, Kay Holcombe, Jeffrey E Jacob, former Pfizer CFO Alan Levin and biochemist Paula J.